Sept. 17, 2021 12:00 UTC
Kimco Realty to Present at the Bank of America Securities 2021 Global Real Estate Conference
Kimco Realty to Present at the Bank of America Securities 2021 Global Real Estate Conference Sept. 17, 2021 12:00 UTC Kimco Realty to Present at the Bank of America Securities 2021 Global Real Estate Conference JERICHO, N.Y.--(BUSINESS WIRE)-- Kimco Realty Corp. (NYSE: KIM) announced today that its management will present at the Bank of America Securities 2021 Global Real Estate Conference on Tuesday, September 21, 2021. Event: Kimco Realty Management Presentation   When: September 21, 2021 at 12:00 P.M. – 12:35 P.M., ET   Where: Live webcast can be accessed by clicking on the following link: Kimco Management to Present at Bank of America Secu
Sept. 17, 2021 12:00 UTC
HarborOne Bancorp, Inc. Announces Share Repurchase Program
HarborOne Bancorp, Inc. Announces Share Repurchase Program Sept. 17, 2021 12:00 UTC HarborOne Bancorp, Inc. Announces Share Repurchase Program BROCKTON, Mass.--(BUSINESS WIRE)-- HarborOne Bancorp, Inc. (the “Company”) (NASDAQ: HONE) announced today that its Board of Directors has adopted a share repurchase program. Under the share repurchase program, which has received regulatory approval, the Company may repurchase up to 2,668,159 shares of the Company’s common stock, or approximately 5% of the Company’s issued and outstanding shares following completion of the share repurchase program announced on April 16, 2021. The April 16, 2021 share repurchase program was completed
Sept. 17, 2021 12:00 UTC
Xeris Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Xeris Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Sept. 17, 2021 12:00 UTC Xeris Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit CHICAGO--(BUSINESS WIRE)-- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable drug formulations, today announced that Paul R. Edick, Chairman and Chief Executive Officer of Xeris Pharmaceuticals, will present an overview of the Company at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 22, 2021, at 8:15
Sept. 17, 2021 11:30 UTC
IMFINZI Combined With Novel Immunotherapies Improved Clinical Outcomes for Patients With Unresectable, Stage III Non-Small Cell Lung Cancer
IMFINZI Combined With Novel Immunotherapies Improved Clinical Outcomes for Patients With Unresectable, Stage III Non-Small Cell Lung Cancer Sept. 17, 2021 11:30 UTC IMFINZI Combined With Novel Immunotherapies Improved Clinical Outcomes for Patients With Unresectable, Stage III Non-Small Cell Lung Cancer COAST Phase II trial showed oleclumab or monalizumab in combination with IMFINZI significantly delayed disease progression and increased objective response rate First effectiveness data from PACIFIC-R reinforced long-term benefit of IMFINZI in the real-world setting WILMINGTON, Del.--(BUSINESS WIRE)-- Results from the large, randomized COAST Phase II trial showed oleclumab, an a
Sept. 17, 2021 12:00 UTC
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia
BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia Sept. 17, 2021 12:00 UTC BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia BeiGene’s European commercial team is preparing to launch BRUKINSA, the company’s first medicine submitted for marketing authorization in the EU, upon approval The CHMP recommendation is based on results from the Phase 3 ASPEN trial, in which BRUKINSA demonstrated a numerically higher very good partial response rate (VGPR) and a favorable safety profile compared to ibrutinib BASEL
Sept. 17, 2021 11:00 UTC
Manchester United PLC Reports Fourth Quarter and Full Year Fiscal 2021 Results
Manchester United PLC Reports Fourth Quarter and Full Year Fiscal 2021 Results Sept. 17, 2021 11:00 UTC Manchester United PLC Reports Fourth Quarter and Full Year Fiscal 2021 Results Key Points Old Trafford returned to full capacity at the start of the 2021/22 season Club welcomed back Cristiano Ronaldo and Tom Heaton and added Jadon Sancho and Raphael Varane to the men’s first team Club extended its contract with men’s first team manager Ole Gunnar Solskjaer and hired Marc Skinner as new head coach for the women’s team Club launched new principal shirt partnership with TeamViewer Renewed three sponsorship deals during 2020/21 including DHL, with new deals rece

Execution time: 0.3476 seconds
Layout: desktop